19th Jan 2021 16:53
ValiRx PLC - clinical stage drug development company - Says its patent portfolio continued to build in 2020, with four patents granted during the last 12 months. Additionally, in January, the European Patent Office notified the company of its intention to grant a patent which extends patent cover for VAL201 into metastatic cancer. These statements of protection are similar to those granted by the US patent office announced in November 2019 and creates a broad coverage of use of the peptide in an important area of oncology.
"It is important for ValiRx to continue to build value in our product portfolio by protecting intellectual property. The patenting process involves rigorous scrutiny of the proposal, testing for novelty and utility before a patent is allowed to be granted," notes Chief Executive Suzy Dilly.
Current stock price: 26.55 pence, down 2.6% on Tuesday
Year-to-date change: up 26%
By Evelina Grecenko; [email protected]
Copyright 2021 Alliance News Limited. All Rights Reserved.
Related Shares:
ValiRx